Evidence map›Paper›PMID 36920244›Full record

ArticleAntimicrobial agents and chemotherapy2023

Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis.

Matthew A Hulverson, Ryan Choi, Deborah A Schaefer, Dana P Betzer, Molly C McCloskey, Grant R Whitman, Wenlin Huang, Sangun Lee, Andy Pranata, Malcolm D McLeod and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Bumped Kinase Inhibitors Inhibit bothACS infectious diseases · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Matthew A HulversonDepartment of Medicine, Division of Allergy and Infectious Disease, Center for Emerging and Reemerging Infectious Disease (CERID), University of Washington, Seattle, Washington, USA.ORCID 0000-0002-3413-4969
Ryan ChoiDepartment of Medicine, Division of Allergy and Infectious Disease, Center for Emerging and Reemerging Infectious Disease (CERID), University of Washington, Seattle, Washington, USA.
Deborah A SchaeferSchool of Animal and Comparative Biomedical Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, Arizona, USA.
Dana P BetzerSchool of Animal and Comparative Biomedical Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, Arizona, USA.
Molly C McCloskeyDepartment of Medicine, Division of Allergy and Infectious Disease, Center for Emerging and Reemerging Infectious Disease (CERID), University of Washington, Seattle, Washington, USA.
Grant R WhitmanDepartment of Medicine, Division of Allergy and Infectious Disease, Center for Emerging and Reemerging Infectious Disease (CERID), University of Washington, Seattle, Washington, USA.ORCID 0000-0001-5634-3764
Wenlin HuangDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Sangun LeeDepartment of Infectious Disease and Global Health, Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA.ORCID 0000-0002-7983-9460
Andy PranataResearch School of Chemistry, Australian National University, Canberra, ACT, Australia.
Malcolm D McLeodResearch School of Chemistry, Australian National University, Canberra, ACT, Australia.
Kennan C MarshResearch and Development, AbbVie, Inc., North Chicago, Illinois, USA.
Dale J KempfResearch and Development, AbbVie, Inc., North Chicago, Illinois, USA.
Bruce E LeRoyResearch and Development, AbbVie, Inc., North Chicago, Illinois, USA.
Mark T ZafiratosResearch and Development, AbbVie, Inc., North Chicago, Illinois, USA.
Aimee L BielinskiResearch and Development, AbbVie, Inc., North Chicago, Illinois, USA.
Robert C HackmanFred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Kayode K OjoDepartment of Medicine, Division of Allergy and Infectious Disease, Center for Emerging and Reemerging Infectious Disease (CERID), University of Washington, Seattle, Washington, USA.
Samuel L M ArnoldDepartment of Medicine, Division of Allergy and Infectious Disease, Center for Emerging and Reemerging Infectious Disease (CERID), University of Washington, Seattle, Washington, USA.ORCID 0000-0001-8290-2347
Lynn K BarrettDepartment of Medicine, Division of Allergy and Infectious Disease, Center for Emerging and Reemerging Infectious Disease (CERID), University of Washington, Seattle, Washington, USA.
Saul TziporiDepartment of Infectious Disease and Global Health, Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA.
Michael W RiggsSchool of Animal and Comparative Biomedical Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, Arizona, USA.
Erkang FanDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Wesley C Van VoorhisDepartment of Medicine, Division of Allergy and Infectious Disease, Center for Emerging and Reemerging Infectious Disease (CERID), University of Washington, Seattle, Washington, USA.ORCID 0000-0001-6141-2015

Funding

Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&ToxoplasmosisR01AI111341 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$6.4M
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvumR01AI089441 · NIAID · UNIVERSITY OF WASHINGTON · PI MERRITT, ETHAN A, PARSONS, MARILYN · 2010 to 2014
$5.0M
Optimization of Lead BKIs for Cryptosporidiosis TherapyR01AI155412 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$4.1M
Bumped-Kinase Inhibitor Drug Development for ToxoplasmosisR01HD102487 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$3.3M
Dual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and NeosporosisR01HD080670 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$1.9M
NIAID NIH HHS R01 AI089441NIAID NIH HHS R01 AI111341NIAID NIH HHS R01 AI155412NICHD NIH HHS R01 HD080670NICHD NIH HHS R01 HD102487
6 · The paper itself

Abstract

Recent advances on the development of bumped kinase inhibitors for treatment of cryptosporidiosis have focused on the 5-aminopyrazole-4-carboxamide scaffold, due to analogs that have less hERG inhibition, superior efficacy, and strong

Indexed as

Antineoplastic AgentsAntiprotozoal AgentsCryptosporidiosisCryptosporidium parvumAnimalsCattleMiceOocystsProtein Kinase InhibitorsRatsAntineoplastic AgentsAntiprotozoal AgentsProtein Kinase InhibitorsBKI-1708BKI-1770BKI-1841bumped kinase inhibitorscalcium-dependent protein kinasescryptosporidiosisCryptosporidiumepiphyseal growth plate

Identifiers

PMID36920244
PMCPMC10112232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.